Metformin reduces the risk of poor treatment outcomes among individuals with rifampicin-resistant tuberculosis and type-2 diabetes mellitus

  1. Argita D. Salindri
  2. Mariam Gujabidze
  3. Maia Kipiani
  4. Nino Lomtadze
  5. Nestani Tukvadze
  6. Zaza Avaliani
  7. Henry M. Blumberg
  8. Hardy Kornfeld
  9. Russell R. Kempker
  10. Matthew J. Magee

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

We conducted a retrospective cohort study among individuals with rifampicin-resistant tuberculosis and diabetes to determine the association between metformin use and tuberculosis treatment outcomes. We found that individuals with metformin use had a significantly lower risk of poor tuberculosis treatment outcomes (adjusted RR=0.25, 95%CI 0.06 – 0.95) compared to those without.

Article activity feed

  1. Rapid Reviews Infectious Diseases

    Yogarabindranath Swarna Nantha

    Review 1: "Metformin Reduces the Risk of Poor Treatment Outcomes among Individuals with Rifampicin-Resistant Tuberculosis and Type-2 Diabetes Mellitus"

    Overall, while the findings are promising, the evidence is preliminary and requires further validation.

  2. Rapid Reviews Infectious Diseases

    Yogarabindranath Swarna Nantha

    Review of "Metformin Reduces the Risk of Poor Treatment Outcomes among Individuals with Rifampicin-Resistant Tuberculosis and Type-2 Diabetes Mellitus"

    Reviewer(s): Y S Nantha (Monash University, Malaysia) | 📒📒📒◻️◻️

  3. Version published to 10.1101/2024.07.12.24310348v1 on medRxiv